In the absence of an available clinical trial, would you favor regorafenib immediately post-sorafenib or nivolumab in patients with HCC?
Regorafenib has been approved for patients with advanced HCC post-sorafenib, but the benefits are slight and toxicity substantial. Nivolumab has encouraging early data, with much more manageable toxicity.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Perelman School of Medicine at the University of Pennsylvania
Answered on
At this point in time, given the continued encouraging data regarding the efficacy of immune checkpoint blockade in HCC coupled with the substantially lower toxicity when compared to regorafenib, I would choose off-label nivolumab in this particular scenario.
Join for free or sign in to see the full answer